TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Impact Evaluation of a Social Franchise Model Implemented by Alive & Thrive for Improving Infant and Young Child Feeding and Child Nutrition in Rural Vietnam
Brief Summary: Alive \& Thrive is an initiative that aims to improve infant and young child feeding practices and reduce childhood stunting. In Vietnam, Alive \& Thrive's primary intervention is implemented through a social franchise linked with the government's health system. The impact evaluation is conducted using a cluster-randomized design in which 20 commune health centers (CHC) were assigned to the social franchise model, and 20 CHC were assigned to routine government services. Repeated cross-sectional baseline and endline surveys will be used to assess the public health impact of this intervention. The baseline was in 2010 and an endline survey in the same communities will be conducted in 2014. Mixed methods process evaluation will be conducted in 2011, 2012 and 2013 to study the pathways through which the program impact is achieved.


Options:
A: Arm Label: Comparison area, only standard government services; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Standard government health services, Behavioral: Mass media campaign | Arm Label: A&T Franchise; Type: EXPERIMENTAL; Interventions: Behavioral: Standard government health services, Behavioral: Alive & Thrive IYCF franchise services, Behavioral: Mass media campaign | Intervention Type: BEHAVIORAL; Name: Standard government health services; Assigned to Arm(s): A&T Franchise, Comparison area, only standard government services | Intervention Type: BEHAVIORAL; Name: Alive & Thrive IYCF franchise services; Assigned to Arm(s): A&T Franchise | Intervention Type: BEHAVIORAL; Name: Mass media campaign; Assigned to Arm(s): A&T Franchise, Comparison area, only standard government services
B: Arm Label: Brief Motivational Intervention; Type: EXPERIMENTAL; Interventions: Other: Brief Motivational Intervention | Arm Label: Breastfeeding education; Type: ACTIVE_COMPARATOR; Interventions: Other: Breastfeeding education | Intervention Type: OTHER; Name: Brief Motivational Intervention; Assigned to Arm(s): Brief Motivational Intervention | Intervention Type: OTHER; Name: Breastfeeding education; Assigned to Arm(s): Breastfeeding education
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: LC and Electronic Prompt | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: LC and Electronic Prompt; Assigned to Arm(s): 1
D: Arm Label: Breastfeeding Education and Support; Type: EXPERIMENTAL; Interventions: Behavioral: Breastfeeding Education and Support | Arm Label: Usual or routine care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Breastfeeding Education and Support; Assigned to Arm(s): Breastfeeding Education and Support

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Impact Evaluation of a Social Franchise Model Implemented by Alive & Thrive for Improving Infant and Young Child Feeding and Child Nutrition in Rural Vietnam
Brief Summary: Alive \& Thrive is an initiative that aims to improve infant and young child feeding practices and reduce childhood stunting. In Vietnam, Alive \& Thrive's primary intervention is implemented through a social franchise linked with the government's health system. The impact evaluation is conducted using a cluster-randomized design in which 20 commune health centers (CHC) were assigned to the social franchise model, and 20 CHC were assigned to routine government services. Repeated cross-sectional baseline and endline surveys will be used to assess the public health impact of this intervention. The baseline was in 2010 and an endline survey in the same communities will be conducted in 2014. Mixed methods process evaluation will be conducted in 2011, 2012 and 2013 to study the pathways through which the program impact is achieved.


Options:
A: Arm Label: Newhints; Type: EXPERIMENTAL; Interventions: Behavioral: Home visits | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Home visits; Assigned to Arm(s): Newhints
B: Arm Label: Comparison area, only standard government services; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Standard government health services, Behavioral: Mass media campaign | Arm Label: A&T Franchise; Type: EXPERIMENTAL; Interventions: Behavioral: Standard government health services, Behavioral: Alive & Thrive IYCF franchise services, Behavioral: Mass media campaign | Intervention Type: BEHAVIORAL; Name: Standard government health services; Assigned to Arm(s): A&T Franchise, Comparison area, only standard government services | Intervention Type: BEHAVIORAL; Name: Alive & Thrive IYCF franchise services; Assigned to Arm(s): A&T Franchise | Intervention Type: BEHAVIORAL; Name: Mass media campaign; Assigned to Arm(s): A&T Franchise, Comparison area, only standard government services
C: Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: CHW-Visit; Type: EXPERIMENTAL; Interventions: Behavioral: Delivery of a Post-Partum Package | Arm Label: CHW-Phone; Type: EXPERIMENTAL; Interventions: Behavioral: Delivery of a Post-Partum Package | Intervention Type: BEHAVIORAL; Name: Delivery of a Post-Partum Package; Assigned to Arm(s): CHW-Phone, CHW-Visit
D: Arm Label: experimental; Type: EXPERIMENTAL; Interventions: Behavioral: training | Intervention Type: BEHAVIORAL; Name: training; Assigned to Arm(s): experimental

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluation of the Efficacy and Safety of a Fixed-dose, Single-capsule Budesonide-formoterol Combination in Uncontrolled Asthma:a Randomized, Double-blind, Multicenter, Controlled Clinical Trial.
Brief Summary: To evaluate the efficacy and safety of a fixed-dose, single-capsule budesonide(400µg)-formoterol(12µg) combination, in comparison with budesonide alone, both delivered via a dry powder inhaler, in 181 patients with uncontrolled asthma.This was Randomized, double-blind, multicenter, phase III, parallel clinical trial.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: FlutiForm 250/10 | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: SKP-Fluticasone | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: Flovent Fluticasone HFA | Intervention Type: DRUG; Name: FlutiForm 250/10; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: SKP-Fluticasone; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Flovent Fluticasone HFA; Assigned to Arm(s): 3
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Budesonide / formoterol fumarate (SYMBICORT) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Budesonide | Intervention Type: DRUG; Name: Budesonide / formoterol fumarate (SYMBICORT); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Budesonide; Assigned to Arm(s): 2
C: Arm Label: MF/F MDI 400/10 mcg BID; Type: EXPERIMENTAL; Interventions: Drug: Mometasone furoate/formoterol (MF/F) combination | Arm Label: MF/F MDI 200/10 mcg BID; Type: EXPERIMENTAL; Interventions: Drug: Mometasone furoate/formoterol (MF/F) combination | Arm Label: MF MDI 400 mcg BID; Type: ACTIVE_COMPARATOR; Interventions: Drug: Mometasone furoate MDI (MF MDI) | Intervention Type: DRUG; Name: Mometasone furoate/formoterol (MF/F) combination; Assigned to Arm(s): MF/F MDI 400/10 mcg BID | Intervention Type: DRUG; Name: Mometasone furoate/formoterol (MF/F) combination; Assigned to Arm(s): MF/F MDI 200/10 mcg BID | Intervention Type: DRUG; Name: Mometasone furoate MDI (MF MDI); Assigned to Arm(s): MF MDI 400 mcg BID
D: Arm Label: Fixed Combination of Budesonide and formoterol; Type: EXPERIMENTAL; Interventions: Drug: Fixed combination of budesonide and formoterol | Arm Label: Budesonide; Type: ACTIVE_COMPARATOR; Interventions: Drug: Budesonide | Intervention Type: DRUG; Name: Fixed combination of budesonide and formoterol; Assigned to Arm(s): Fixed Combination of Budesonide and formoterol | Intervention Type: DRUG; Name: Budesonide; Assigned to Arm(s): Budesonide

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluation of the Efficacy and Safety of a Fixed-dose, Single-capsule Budesonide-formoterol Combination in Uncontrolled Asthma:a Randomized, Double-blind, Multicenter, Controlled Clinical Trial.
Brief Summary: To evaluate the efficacy and safety of a fixed-dose, single-capsule budesonide(400µg)-formoterol(12µg) combination, in comparison with budesonide alone, both delivered via a dry powder inhaler, in 181 patients with uncontrolled asthma.This was Randomized, double-blind, multicenter, phase III, parallel clinical trial.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: salbutamol | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Formoterol | Intervention Type: DRUG; Name: salbutamol; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Formoterol; Assigned to Arm(s): 2
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: budesonide/formoterol (Symbicort) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: fluticasone/salmeterol (Advair) | Intervention Type: DRUG; Name: budesonide/formoterol (Symbicort); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: fluticasone/salmeterol (Advair); Assigned to Arm(s): 2
C: Arm Label: Fixed Combination of Budesonide and formoterol; Type: EXPERIMENTAL; Interventions: Drug: Fixed combination of budesonide and formoterol | Arm Label: Budesonide; Type: ACTIVE_COMPARATOR; Interventions: Drug: Budesonide | Intervention Type: DRUG; Name: Fixed combination of budesonide and formoterol; Assigned to Arm(s): Fixed Combination of Budesonide and formoterol | Intervention Type: DRUG; Name: Budesonide; Assigned to Arm(s): Budesonide
D: Intervention Type: DRUG; Name: budesonide/formoterol Turbuhaler; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Helicobacter Pylori Eradication to Prevent Gastric Cancer in Subjects With Family History of Gastric Cancer: A Randomized Controlled Study
Brief Summary: This study evaluate whether treatment of Helicobacter pylori infection reduces the incidence of gastric cancer in subjects with family history of gastric cancer.


Options:
A: Arm Label: Amox/omepr; Type: EXPERIMENTAL; Interventions: Drug: Amoxicillin/omeprazole | Arm Label: Garlic; Type: EXPERIMENTAL; Interventions: Drug: Amoxicillin/omeprazole | Arm Label: Vitamins; Type: EXPERIMENTAL; Interventions: Drug: Amoxicillin/omeprazole | Intervention Type: DRUG; Name: Amoxicillin/omeprazole; Assigned to Arm(s): Amox/omepr, Garlic, Vitamins
B: Arm Label: control group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: treatment group; Type: ACTIVE_COMPARATOR; Interventions: Drug: eradication treatment of Helicobacter pylori infection | Intervention Type: DRUG; Name: eradication treatment of Helicobacter pylori infection; Assigned to Arm(s): treatment group
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: LAC triple therapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: LAC triple therapy | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: LAC triple therapy; Assigned to Arm(s): LAC triple therapy
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Clarithromycin, Metronidazole, Amoxicillin (+Omeprazole) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Clarithromycin, Amoxicillin, Omeprazole | Intervention Type: DRUG; Name: Clarithromycin, Metronidazole, Amoxicillin (+Omeprazole); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Clarithromycin, Amoxicillin, Omeprazole; Assigned to Arm(s): 2

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase 1, Single Center Study Using Omalizumab in Subjects With Atopic Dermatitis
Brief Summary: A phase 1 single center study in which omalizumab is dosed normally (according to the product insert) in subjects with atopic dermatitis.


Options:
A: Arm Label: Group1; Type: EXPERIMENTAL; Interventions: Drug: nemolizumab (CIM331) | Arm Label: Group2; Type: EXPERIMENTAL; Interventions: Drug: nemolizumab (CIM331) | Arm Label: Group3; Type: EXPERIMENTAL; Interventions: Drug: nemolizumab (CIM331) | Arm Label: Group4; Type: EXPERIMENTAL; Interventions: Drug: nemolizumab (CIM331) | Arm Label: Group5; Type: EXPERIMENTAL; Interventions: Drug: nemolizumab (CIM331), Other: Placebo | Intervention Type: DRUG; Name: nemolizumab (CIM331); Assigned to Arm(s): Group1, Group2, Group3, Group4, Group5 | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Group5
B: Intervention Type: BIOLOGICAL; Name: omalizumab; Assigned to Arm(s): N/A
C: Arm Label: Treatment group A; Type: EXPERIMENTAL; Interventions: Drug: Tofacitinib ointment 20mg/g | Arm Label: Treatment B; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo ointment (Vehicle) | Intervention Type: DRUG; Name: Tofacitinib ointment 20mg/g; Assigned to Arm(s): Treatment group A | Intervention Type: DRUG; Name: Placebo ointment (Vehicle); Assigned to Arm(s): Treatment B
D: Arm Label: Placebo qw; Type: EXPERIMENTAL; Interventions: Drug: Placebo | Arm Label: Dupilumab 300 mg qw; Type: EXPERIMENTAL; Interventions: Drug: Dupilumab | Arm Label: Dupilumab 300 mg q2w; Type: EXPERIMENTAL; Interventions: Drug: Dupilumab, Drug: Placebo | Arm Label: Dupilumab 200 mg q2w; Type: EXPERIMENTAL; Interventions: Drug: Dupilumab, Drug: Placebo | Arm Label: Dupilumab 300 mg q4w; Type: EXPERIMENTAL; Interventions: Drug: Dupilumab, Drug: Placebo | Arm Label: Dupilumab 100 mg q4w; Type: EXPERIMENTAL; Interventions: Drug: Dupilumab, Drug: Placebo | Intervention Type: DRUG; Name: Dupilumab; Assigned to Arm(s): Dupilumab 100 mg q4w, Dupilumab 200 mg q2w, Dupilumab 300 mg q2w, Dupilumab 300 mg q4w, Dupilumab 300 mg qw | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Dupilumab 100 mg q4w, Dupilumab 200 mg q2w, Dupilumab 300 mg q2w, Dupilumab 300 mg q4w, Placebo qw

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: 1) Impact Evaluation of Behavior Change Communication and Micronutrient Supplementation Interventions on Infant and Young Child Feeding (IYCF) Practices and on Childhood Stunting and Anaemia 2) Evaluation of the Public Health Impact of a Market-based Approach to Improving Diet Quality of Infants and Young Children Through the Use of Sprinkles in Bangladesh
Brief Summary: This complex evaluation of a large-scale program uses a cluster-randomized design where 20 geographic clusters (subdistricts) were randomized to study two sets of interventions. For the evaluation of behavior change interventions only, the 20 clusters were randomized to 10 intensive and 10 non-intensive interventions areas. For a sub-study to evaluate a market-based model for delivering micronutrient powders (MNP) along with behavior change interventions, there was subsequent randomization to comparison area, MNP-only area, Behavior Change Communication (BCC)-only area and MNP+BCC areas.


Options:
A: Intervention Type: BEHAVIORAL; Name: Lactation counseling; Assigned to Arm(s): N/A
B: Arm Label: Essential Health Care (EHC) only; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Mass media | Arm Label: EHC + Micronutrient Powders; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Micronutrient powders, Behavioral: Mass media | Arm Label: EHC + BCC; Type: EXPERIMENTAL; Interventions: Behavioral: EHC + BCC, Behavioral: Mass media | Arm Label: EHC + BCC + Micronutrient powders; Type: EXPERIMENTAL; Interventions: Behavioral: EHC + BCC, Dietary Supplement: Micronutrient powders, Behavioral: Mass media | Intervention Type: BEHAVIORAL; Name: EHC + BCC; Assigned to Arm(s): EHC + BCC, EHC + BCC + Micronutrient powders | Intervention Type: DIETARY_SUPPLEMENT; Name: Micronutrient powders; Assigned to Arm(s): EHC + BCC + Micronutrient powders, EHC + Micronutrient Powders | Intervention Type: BEHAVIORAL; Name: Mass media; Assigned to Arm(s): EHC + BCC, EHC + BCC + Micronutrient powders, EHC + Micronutrient Powders, Essential Health Care (EHC) only
C: Arm Label: Home-based peer counselling intervention; Type: ACTIVE_COMPARATOR; Interventions: Other: Home-based peer counselling (web-based) intervention | Arm Label: Standard usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Home-based peer counselling (web-based) intervention; Assigned to Arm(s): Home-based peer counselling intervention
D: Arm Label: Usual Care; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Usual Care | Arm Label: Healthy Beyond Pregnancy; Type: EXPERIMENTAL; Interventions: Behavioral: Healthy Beyond Pregnancy | Intervention Type: BEHAVIORAL; Name: Healthy Beyond Pregnancy; Assigned to Arm(s): Healthy Beyond Pregnancy | Intervention Type: BEHAVIORAL; Name: Usual Care; Assigned to Arm(s): Usual Care

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: 1) Impact Evaluation of Behavior Change Communication and Micronutrient Supplementation Interventions on Infant and Young Child Feeding (IYCF) Practices and on Childhood Stunting and Anaemia 2) Evaluation of the Public Health Impact of a Market-based Approach to Improving Diet Quality of Infants and Young Children Through the Use of Sprinkles in Bangladesh
Brief Summary: This complex evaluation of a large-scale program uses a cluster-randomized design where 20 geographic clusters (subdistricts) were randomized to study two sets of interventions. For the evaluation of behavior change interventions only, the 20 clusters were randomized to 10 intensive and 10 non-intensive interventions areas. For a sub-study to evaluate a market-based model for delivering micronutrient powders (MNP) along with behavior change interventions, there was subsequent randomization to comparison area, MNP-only area, Behavior Change Communication (BCC)-only area and MNP+BCC areas.


Options:
A: Intervention Type: BEHAVIORAL; Name: Maternal nutrition and infant feeding advice; Assigned to Arm(s): N/A
B: Arm Label: Family Spirit Nurture (FSN); Type: EXPERIMENTAL; Interventions: Behavioral: Family Spirit Nurture (FSN), Other: Optimized Standard Care (OSC) | Arm Label: Control Program; Type: OTHER; Interventions: Other: Injury Prevention Education (IPE), Other: Optimized Standard Care (OSC) | Intervention Type: BEHAVIORAL; Name: Family Spirit Nurture (FSN); Assigned to Arm(s): Family Spirit Nurture (FSN) | Intervention Type: OTHER; Name: Injury Prevention Education (IPE); Assigned to Arm(s): Control Program | Intervention Type: OTHER; Name: Optimized Standard Care (OSC); Assigned to Arm(s): Control Program, Family Spirit Nurture (FSN)
C: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Dietary Advice | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Dietary Advice; Assigned to Arm(s): Intervention
D: Arm Label: Essential Health Care (EHC) only; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Mass media | Arm Label: EHC + Micronutrient Powders; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Micronutrient powders, Behavioral: Mass media | Arm Label: EHC + BCC; Type: EXPERIMENTAL; Interventions: Behavioral: EHC + BCC, Behavioral: Mass media | Arm Label: EHC + BCC + Micronutrient powders; Type: EXPERIMENTAL; Interventions: Behavioral: EHC + BCC, Dietary Supplement: Micronutrient powders, Behavioral: Mass media | Intervention Type: BEHAVIORAL; Name: EHC + BCC; Assigned to Arm(s): EHC + BCC, EHC + BCC + Micronutrient powders | Intervention Type: DIETARY_SUPPLEMENT; Name: Micronutrient powders; Assigned to Arm(s): EHC + BCC + Micronutrient powders, EHC + Micronutrient Powders | Intervention Type: BEHAVIORAL; Name: Mass media; Assigned to Arm(s): EHC + BCC, EHC + BCC + Micronutrient powders, EHC + Micronutrient Powders, Essential Health Care (EHC) only

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Safety Study of MK-8237 Treatment in House-Dust-Mite Allergic Adolescents (Protocol 008)
Brief Summary: The purpose of this study is to evaluate the safety of two doses (6 Development Units \[DU\] and 12 DU) of MK-8237 sublingual tablets compared to Placebo in adolescents with house dust mite-induced allergic rhinitis/rhinoconjunctivitis. The primary hypothesis is that at least one dose of MK-8237 sublingual tablet is safe and well-tolerated in adolescents with house dust mite-induced allergic rhinitis/rhinoconjunctivitis.


Options:
A: Arm Label: Short ragweed pollen allergen extract; Type: EXPERIMENTAL; Interventions: Biological: Short ragweed pollen allergen extract, Drug: Self-injectable epinephrine, Drug: Albuterol/Salbutamol, Drug: Loratadine, Drug: Olopatadine, Drug: Mometasone furoate monohydrate | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo, Drug: Self-injectable epinephrine, Drug: Albuterol/Salbutamol, Drug: Loratadine, Drug: Olopatadine, Drug: Mometasone furoate monohydrate | Intervention Type: BIOLOGICAL; Name: Short ragweed pollen allergen extract; Assigned to Arm(s): Short ragweed pollen allergen extract | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Self-injectable epinephrine; Assigned to Arm(s): Placebo, Short ragweed pollen allergen extract | Intervention Type: DRUG; Name: Albuterol/Salbutamol; Assigned to Arm(s): Placebo, Short ragweed pollen allergen extract | Intervention Type: DRUG; Name: Loratadine; Assigned to Arm(s): Placebo, Short ragweed pollen allergen extract | Intervention Type: DRUG; Name: Olopatadine; Assigned to Arm(s): Placebo, Short ragweed pollen allergen extract | Intervention Type: DRUG; Name: Mometasone furoate monohydrate; Assigned to Arm(s): Placebo, Short ragweed pollen allergen extract
B: Arm Label: 1; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: (agent for immunotherapy) Staloral | Intervention Type: DRUG; Name: (agent for immunotherapy) Staloral; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 1
C: Arm Label: MK-8237 6 DU; Type: EXPERIMENTAL; Interventions: Biological: MK-8237 6 DU | Arm Label: MK-8237 12 DU; Type: EXPERIMENTAL; Interventions: Biological: MK-8237 12 DU | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Intervention Type: BIOLOGICAL; Name: MK-8237 6 DU; Assigned to Arm(s): MK-8237 6 DU | Intervention Type: BIOLOGICAL; Name: MK-8237 12 DU; Assigned to Arm(s): MK-8237 12 DU | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Staloral | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Staloral | Intervention Type: DRUG; Name: Staloral; Assigned to Arm(s): 1, 2

Answer: C